To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Viagra Effective Treatment For Diabetes-Related Impotence URL: http://www.pslgroup.com/dg/E121E.htm Doctor's Guide February 2, 1999
CHICAGO, IL -- Feb. 2, 1999 -- Pfizer Inc.'s Viagra (sildenafil) is an effective and well-tolerated treatment for erectile dysfunction (ED) in men with diabetes, according to an article in tomorrow's issue of The Journal of the American Medical Association. Marc Rendell, M.D., from Creighton Diabetes Center, Omaha, NE., and colleagues studied the efficacy and safety of oral sildenafil citrate versus placebo in 268 men with erectile dysfunction and type I (insulin-dependent) or type II (non-insulin-dependent) diabetes. The study was conducted in patients' homes and in 19 clinical practice centres in the United States from May through November 1996. The researchers found that after 12 weeks of treatment, 56 percent of the patients in the sildenafil group reported improved erections compared with 10 percent of patients taking placebo. The proportion of men with at least one successful attempt at sexual intercourse was 61 percent for the sildenafil group versus 22 percent for the placebo group. "Treatment with sildenafil significantly improved erection function across all three efficacy variables regardless of patient age, the duration of ED and the duration of diabetes," the authors write. According to the authors, ED is a common complication in men with diabetes. The authors write that erectile dysfunction in men with diabetes is often associated with diabetic neuropathy and peripheral vascular disease. It occurs at an earlier age in men with diabetes than in men in the general population and several studies have demonstrated that ED affects 35 percent to 75 percent of men with diabetes. Diabetes mellitus (a disorder in which the pancreas produces insufficient or no insulin) affects an estimated 15.7 million people in the United States, including 7.5 million men, with type II diabetes, accounting for 90 percent to 95 percent of the diagnosed cases, and type I diabetes, accounting for five percent to 10 percent. The researchers found that treatment with sildenafil was well tolerated and that the safety profile of sildenafil in patients with diabetes was reassuring given the chronic complications associated with diabetes. Adverse events related to treatment were reported for 16 percent of the sildenafil group and one percent of patients receiving placebo. The most common adverse effects associated with sildenafil treatment were headache, dyspepsia (indigestion), respiratory tract disorder (sinus congestion or drainage), which were predominately transient and mild or moderate in nature. The incidences of cardiovascular adverse events were comparable for both groups. Related Links: Viagra, Pfizer Inc., The Journal of the American Medical Association --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.